Imeglimin - Poxel
Alternative Names: EMD-387008; Imeglimin hydrochloride - Poxel; PXL 008; RVT-1501; TWYMEEGLatest Information Update: 18 Jul 2024
At a glance
- Originator Merck KGaA
- Developer Poxel; Sumitomo Pharma
- Class Amines; Antihyperglycaemics; Small molecules; Triazines; Urologics
- Mechanism of Action Insulin secretion stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- No development reported Kidney disorders